Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Article
  • Published:

Long-term lung infection suppression in a mouse model caused via the clinical isolate of Burkholderia cenocepacia using the non-traditional antibacterial agent Fluorothiazinone

The Journal of Antibiotics (2026)Cite this article

Subjects

Abstract

The aim of the study was to evaluate the effects of Fluorothiazinone (FT), the inhibitor of type III secretion system (T3SS), on a model of a long-term infection in animal caused via the clinical isolate of Burkholderia cenocepacia acquired from the chronically infected cystic fibrosis patient. To simulate acute and long-term lung infection, DBA/2 mice were infected intranasally, the bacterial recovery from the lungs was assessed, and a histopathological study was performed. Intracellular survival and reproduction of bacteria in macrophages were evaluated on a monolayer of RAW264.7 cells. When simulating an acute infection, the isolate caused death of 50% of mice within 5 days, while combined preventive–therapeutic scheme with FT increased the survival rate to 100%. When simulating a prolonged infection, combined preventive–therapeutic scheme with FT resulted in decrease in lung colonization compared to the control group by several orders of magnitude on the 5th day after the infection and to complete eradication on the 10th day. Histopathological examination confirmed the efficacy of FT in reducing the intensity of lung damage. FT prevented survival of the isolate in RAW264.7 macrophages and reduced the ability of bacteria to replicate intracellularly. Thus the efficacy of the new non-traditional antibacterial agent FT has been shown in models of acute and in prevention of a long-term lung infections caused via a multidrug-resistant isolate B. cenocepacia. FT has reduced the ability of the isolate to survive intracellularly and replicate in macrophages, thereby affecting significant mechanisms of the development of chronic infections.

This is a preview of subscription content, access via your institution

Access options

Fig. 1
Fig. 2
Fig. 3
Fig. 4
Fig. 5
Fig. 6

Similar content being viewed by others

References

  1. Devanga Ragupathi NK, Veeraraghavan B. Accurate identification and epidemiological characterization of Burkholderia cepacia complex: an update. Ann Clin Microbiol Antimicrob. 2019;18:7.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Syed I, Wooten RM. Interactions between pathogenic Burkholderia and the complement system: a review of potential immune evasion mechanisms. Front Cell Infect Microbiol. 2021;11:701362.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  3. Schaefers MM. Regulation of virulence by two-component systems in pathogenic Burkholderia. Infect Immun. 2020;88:e00927–19.

    Article  PubMed  PubMed Central  Google Scholar 

  4. Hauser N, Orsini J. Cepacia syndrome in a non-cystic fibrosis patient. Case Rep Infect Dis. 2015;2015:1–4.

    Google Scholar 

  5. Lord R, Jones AM, Horsley A. Antibiotic treatment for Burkholderia cepacia complex in people with cystic fibrosis experiencing a pulmonary exacerbation. Cochrane Database Syst Rev. 2020;2020:CD009529.

    Google Scholar 

  6. Li X, Wang K, Wang G, Cui B, Song S, Sun X, Deng Y. Oridonin attenuates Burkholderia cenocepacia virulence by suppressing quorum- sensing signaling. Microbiol Spectr. 2022;10:e0178722.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Silva-Santana G, Sales FLS, Aguiar AR, Brandão MLL. Pharmaceutical contamination by biofilms formed of the Burkholderia cepacia complex: public health risks. Processes. 2025;13:1270.

    Article  CAS  Google Scholar 

  8. Murugaiyan J, Kumar PA, Rao GS, Iskandar K, Hawser S, Hays JP, Mohsen Y, Adukkadukkam S, Awuah WA, Jose RAM, Sylvia N, Nansubuga EP, Tilocca B, Roncada P, Roson-Calero N, Moreno-Morales J, Amin R, Kumar BK, Kumar A, Toufik AR, Zaw TN, Akinwotu OO, Satyaseela MP, van Dongen MBM. Progress in alternative strategies to combat antimicrobial resistance: focus on antibiotics. Antibiotics. 2022;11:200.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  9. Zigangirova NA, Lubenec NL, Beloborodov VB, Sheremet AB, Nelyubina SA, Bondareva NE, Zakharov KA, Luyksaar SI, Zolotov SA, Levchenko EU, Luyksaar SV, Koroleva EA, Fedina ED, Simakova YV, Pushkar DY, Gintzburg AL. A new "non-traditional" antibacterial drug fluorothiazinone-clinical research in patients with complicated urinary tract infections. Antibiotics (Basel). 2024;13:476.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  10. Koroleva EA, Kobets NV, Zayakin ES, Luyksaar SI, Shabalina LA, Zigangirova NA. Small-molecule inhibitor of type three secretion suppresses acute and chronic Chlamydia trachomatis infection in a novel urogenital Chlamydia model. BioMed Res. Int. 2015;2015:1–7.

    Article  Google Scholar 

  11. Sheremet AB, Zigangirova NA, Zayakin ES, Luyksaar SI, Kapotina LN, Nesterenko LN, Kobets NV, Gintsburg AL. Small molecule inhibitor of type three secretion system belonging to a class 2,4-disubstituted-4H-[1,3,4]-thiadiazine-5-ones improves survival and decreases bacterial loads in an airway Pseudomonas aeruginosa infection in mice. BioMed Res.Int. 2018;2018:1–13.

    Article  Google Scholar 

  12. Bondareva NE, Soloveva AV, Sheremet AB, Koroleva EA, Kapotina LN, Morgunova EY, Luyksaar SI, Zayakin ES, Zigangirova NA. Preventative treatment with Fluorothiazinon suppressed Acinetobacter baumannii-associated septicemia in mice. J. Antibiot. 2022;75:155–63.

    Article  CAS  Google Scholar 

  13. Koroleva EA, Soloveva AV, Morgunova EY, Kapotina LN, Luyksaar SI, Luyksaar SV, Bondareva NE, Nelubina SA, Lubenec NL, Zigangirova NA, Gintsburg AL. Fluorothiazinon inhibits the virulence factors of uropathogenic Escherichia coli involved in the development of urinary tract infection. J. Antibiot. 2023;76:279–90.

    Article  CAS  Google Scholar 

  14. Tsarenko SV, Zigangirova NA, Soloveva AV, Bondareva NE, Koroleva EA, Sheremet AB, Kapotina LN, Shevlyagina NV, Andreevskaya SG, Zhukhovitsky VG, Filimonova EV, Gintsburg AL. A novel antivirulent compound fluorothiazinone inhibits Klebsiella pneumoniae biofilm in vitro and suppresses model pneumonia. J. Antibiot. 2023;76:397–405.

    Article  CAS  Google Scholar 

  15. Savitskii MV, Moskaleva NE, Brito A. Pharmacokinetics, quorum-sensing signal molecules and tryptophan-related metabolomics of the novel anti-virulence drug Fluorothiazinon in a Pseudomonas aeruginosa-induced pneumonia murine model. J Pharm Biomed Anal. 2023;236:115739.

    Article  CAS  PubMed  Google Scholar 

  16. Facchini M, De Fino I, Riva C, Bragonzi A. Long term chronic Pseudomonas aeruginosa airway infection in mice. J Vis Exp. 2014;85:51019.

    Google Scholar 

  17. Pirone L, Bragonzi A, Farcomeni A, Paroni M, Auriche C, Conese M, Chiarini L, Dalmastri C, Bevivino A, Ascenzioni F. Burkholderia cenocepacia strains isolated from cystic fibrosis patients are apparently more invasive and more virulent than rhizosphere strains. Environ. Microbiol. 2008;10:2773–84.

    Article  CAS  PubMed  Google Scholar 

  18. Bragonzi A, Worlitzsch D, Pier GB, Timpert P, Ulrich M, Hentzer M, Andersen JB, Givskov M, Conese M, Doring G. Nonmucoid Pseudomonas aeruginosa expresses alginate in the lungs of patients with cystic fibrosis and in a mouse model. J Infect Dis. 2005;192:410–9.

    Article  PubMed  PubMed Central  Google Scholar 

  19. Bragonzi A, Paroni M, Nonis A, Cramer N, Montanari S, Rejman J, Di Serio C, Döring G, Tümmler B. Pseudomonas aeruginosa microevolution during cystic fibrosis lung infection establishes clones with adapted virulence. Am J Respir Crit Care Med. 2009;180:138–45.

    Article  PubMed  Google Scholar 

  20. Riedel K, Hentzer M, Geisenberger O, Huber B, Steidle A, Wu H, Høiby N, Givskov M, Molin S, Eberl L. N-acylhomoserine-lactone-mediated communication between Pseudomonas aeruginosa and Burkholderia cepacia in mixed biofilms. Microbiology (Reading). 2001;147:3249–62.

    Article  CAS  PubMed  Google Scholar 

  21. Chu KK, Davidson DJ, Halsey TK, Chung JW, Speert DP. Differential persistence among genomovars of the Burkholderia cepacia complex in a murine model of pulmonary infection. Infect Immun. 2002;70:2715–20.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Perikleous EP, Gkentzi D, Bertzouanis A, Paraskakis E, Sovtic A, Fouzas S. Antibiotic resistance in patients with cystic fibrosis: past, present, and future. Antibiotics. 2023;12:217.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  23. Scoffone VC, Chiarelli LR, Trespidi G, Mentasti M, Riccardi G, Buroni S. Burkholderia cenocepacia infections in cystic fibrosis patients: drug resistance and therapeutic approaches. Front Microbiol. 2017;8:1592.

    Article  PubMed  PubMed Central  Google Scholar 

  24. Balwan A, Nicolau DP, Wungwattana M, Zuckerman JB, Waters V. Clinafloxacin for treatment of Burkholderia cenocepacia infection in a cystic fibrosis patient. Antimicrob Agents Chemother. 2016;60:1–5.

    Article  CAS  PubMed  Google Scholar 

  25. Chernish RN, Aaron SD. Approach to resistant Gram-negative bacterial pulmonary infections in patients with cystic fibrosis. Curr Opin Pulm Med. 2003;9:509–15.

    Article  PubMed  Google Scholar 

  26. Aaron SD, Ferris W, Henry DA, Speert DP, Macdonald NE. Multiple combination bactericidal antibiotic testing for patients with cystic fibrosis infected with Burkholderia cepacia. Am J Respir Crit Care Med. 2000;161:1206–12.

    Article  CAS  PubMed  Google Scholar 

  27. Tomich M, Griffith A, Herfst CA, Burns JL, Mohr CD. Attenuated virulence of a Burkholderia cepacia type III secretion mutant in a murine model of infection. Infect Immun. 2003;71:1405–15.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Selim H, Radwan TEE, Reyad AM. Regulation of T3SS synthesis, assembly and secretion in Pseudomonas aeruginosa Arch Microbiol. Arch Microbiol. 2022;204:468.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  29. Loutet SA, Valvano MA. A decade of Burkholderia cenocepacia virulence determinant research. Infect Immun. 2010;78:4088–100.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  30. Huynh KK, Plumb JD, Downey GP, Valvano MA, Grinstein S. Inactivation of macrophage Rab7 by Burkholderia cenocepacia. J Innate Immun. 2010;2:522–33.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. N.F. Gamaleya National Research Center for Epidemiology and Microbiology, Ministry of Health of Russian Federation; (NRCEM), Moscow, Russia

    Anna V. Soloveva, Stanislava A. Nelyubina, Elena Yu. Morgunova, Marina E. Komyakova, Elena D. Fedina, Alisa S. Parfenova, Ekaterina A. Koroleva, Lidiya N. Kapotina, Galina A. Danilina & Nailya A. Zigangirova

Authors
  1. Anna V. Soloveva
    View author publications

    Search author on:PubMed Google Scholar

  2. Stanislava A. Nelyubina
    View author publications

    Search author on:PubMed Google Scholar

  3. Elena Yu. Morgunova
    View author publications

    Search author on:PubMed Google Scholar

  4. Marina E. Komyakova
    View author publications

    Search author on:PubMed Google Scholar

  5. Elena D. Fedina
    View author publications

    Search author on:PubMed Google Scholar

  6. Alisa S. Parfenova
    View author publications

    Search author on:PubMed Google Scholar

  7. Ekaterina A. Koroleva
    View author publications

    Search author on:PubMed Google Scholar

  8. Lidiya N. Kapotina
    View author publications

    Search author on:PubMed Google Scholar

  9. Galina A. Danilina
    View author publications

    Search author on:PubMed Google Scholar

  10. Nailya A. Zigangirova
    View author publications

    Search author on:PubMed Google Scholar

Corresponding author

Correspondence to Nailya A. Zigangirova.

Ethics declarations

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Soloveva, A.V., Nelyubina, S.A., Morgunova, E.Y. et al. Long-term lung infection suppression in a mouse model caused via the clinical isolate of Burkholderia cenocepacia using the non-traditional antibacterial agent Fluorothiazinone. J Antibiot (2026). https://doi.org/10.1038/s41429-026-00907-1

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Version of record:

  • DOI: https://doi.org/10.1038/s41429-026-00907-1

Search

Advanced search

Quick links